Min­ing from plants and fun­gi, CNS start­up takes leap in­to psy­choac­tive drugs — com­plete with $30M to kick things off

A biotech with founders out of Mass Gen­er­al and Har­vard is look­ing to take the next step in the men­tal health and CNS space, and thanks to in­vestors, the com­pa­ny has $30 mil­lion in new funds to work with.

Sen­so­ri­um Ther­a­peu­tics put out word of its launch and sub­se­quent Se­ries A Tues­day morn­ing, look­ing to work in psy­choac­tive drugs with an em­pha­sis on men­tal health, such as anx­i­ety and de­pres­sion. CEO and co-founder Dick Si­mon tells End­points News that the biotech’s ap­proach looks in the same space as psy­che­delics but not quite psy­che­delics per se.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER